Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study

The phase 3 HESTIA3 study assessed the efficacy and safety of the reversible P2Y(12) inhibitor ticagrelor vs placebo in preventing vaso-occlusive crises in pediatric patients with sickle cell disease (SCD). Patients aged 2 to 17 years were randomly assigned 1:1 to receive weight-based doses of ticag...

Descripción completa

Detalles Bibliográficos
Autores principales: Heeney, Matthew M., Abboud, Miguel R., Githanga, Jessie, Inusa, Baba P. D., Kanter, Julie, Michelson, Alan D., Nduba, Videlis, Musiime, Victor, Apte, Mohini, Inati, Adlette, Taksande, Amar M., Andersson, Marielle, Åstrand, Magnus, Maklad, Noha, Niazi, Mohammad, Himmelmann, Anders, Berggren, Anders R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523370/
https://www.ncbi.nlm.nih.gov/pubmed/35849650
http://dx.doi.org/10.1182/blood.2021014095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9523370/
https://www.ncbi.nlm.nih.gov/pubmed/35849650
http://dx.doi.org/10.1182/blood.2021014095

Ejemplares similares